Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient

American Journal of Hematology

Volumn 81, Issue 12, 2006, Pages 969-972

  Law, Joanna K ^a   Ali, Jaber Al ^a   Harrigan, P Richard ^a   Sherlock, Christopher H ^a   Savage, Kerry J ^a   Yoshida, Eric M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Hepatitis B; Lamivudine; Resistance; YMDD mutation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATOVIR; LAMIVUDINE; PREDNISONE; RITUXIMAB; TENOFOVIR; TENOFOVIR DISOPROXIL; VINCRISTINE;

ADULT; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHINESE; DRUG FATALITY; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; VIRUS CARRIER; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS STRAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS ACTIVATION;

EID: 33845240185     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20737     Document Type: Article

References (21)

1. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-275.
2. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Reports of a prospective study. Gastroenterology 1991;100:182-188.
3. Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiologic study in Japan. Ann Oncol 1997;1(8 suppl):107-109.
4. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;29:2925-2930.
5. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-1328.
6. Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004;41:454-461.
7. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004;5:325-358.
8. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-479.
9. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
10. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
11. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistence to lamivudine in vivo. Hepatology 1996;24:714-747.
12. Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, et al. Genotypic sucession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatology 2000;30:269-275.
13. Shang X, Liu C, Gong Q, Zhang S, Zhang D, Lu Z, Wang Y. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol 2003;18:1353-1357.
14. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng YK, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;199:172-180.
15. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
16. Kagawa T, Watanbe N, Kanouda H, Takayama I, Shiba T, Kanai T, et al. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 2004;10:1686-1687.
17. Bruno R, Sachhi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001;121:1027-1028.
18. Joh R, Hasegawa K, Torii N, et al. Repeated jaundice due to YMDD mutant in a patient with prolonged lamivudine therapy for chronic hepatitis B under prednisolone treatment for Still's disease. Intern Med 2002;41:701-705.
19. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipovoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
20. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepattis B virus infection. Hepatology 2004;40:1421-1425.
21. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.